ArticleInternational journal of food science2022
Catechin-Albumin Conjugates: Enhanced Antioxidant Capacity and Anticancer Effects.
Article in International journal of food science, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed, 2 citations in OpenAlex.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
(+)-Catechin conjugated with human serum albumin (CT-HSA) was prepared and evaluated as a drug carrier bearing anticancer effects. It was found that 2.4 mol of CT was conjugate to 1 mol HSA. The CT-HSA has an antioxidant capacity of about 3.3 times the amount of CT in the conjugate. Intracellular incorporation of the CT-HSA was analyzed by fluorescence-activated cell sorting (FACS) and confocal laser scanning microscopy (CLSM) measurements using fluorescein isothiocyanate (FITC)-labelled CT-HSA. The results indicated that the FITC-labelled CT-HSA was incorporated into HeLa cells in a concentration-dependent manner. The CT-HSA enhanced the binding of anticancer drugs (5-fluorouracil (5-Fu) and mitomycin C (MMC)) comparing with HSA, and the CT-HSA mixed with 5-Fu or MMC decreased significantly the HeLa cell viability as compared with the same concentration of each drug. In addition, intracellular reactive oxygen species (ROS) scavenging by the CT-HSA is likely to affect the anticancer effects. Thus, the CT-HSA enhanced anticancer drug efficacy in relation to controlling ROS-scavenging ability.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.